Migraine Campaign to Help Sufferers Overcome Barriers to Finding Migraine Pain Relief

Armen Hareyan's picture

Migraine Treatment

Pfizer Inc introduced today a new education campaign, Be Stronger Than Your Migraine, to help migraine sufferers overcome barriers that can prevent them from seeking effective pain relief. About 28 million people suffer from the severe, throbbing pain of migraine, which can last from hours to days, keeping sufferers from family, work and daily life.

Yet, two-thirds of patients surveyed say they are less than satisfied with their current treatment. Sufferers may often feel discouraged and unmotivated to discuss the pain and impact with others, even their doctors.

"The impact of migraine on a person's life can be tremendous," says Rhonda Britten, life coach and star of the reality show Starting Over, "and too many are accepting pain as a way of life because they have become too frustrated to do anything more to help themselves."

That's why Britten, a migraine sufferer herself, is helping to launch the campaign. Applying problem-solving techniques that she developed through her Fearless Living Institute, Britten worked with Pfizer to create exercises designed to motivate sufferers to talk with their physician about their treatment needs. Specifically, the tools take patients through a stepwise process that helps them to recognize whether migraine continues to impact their daily life, identify why they have not taken action to find adequate pain relief, and engage in more productive dialogue with their doctor. They are available in a free informational brochure that will empower sufferers to break away from the thinking that keeps them from taking action.

Dr. Marc Husid, founder and director of the Walton Headache Center and assistant clinical professor of neurology at the Medical College of Georgia in Augusta, agrees that too many patients suffer needlessly from migraine and other chronic headache disorders. "Studies show that more than half of migraine sufferers have never been diagnosed, and only 40 percent treat their pain with prescription medication," said Dr. Husid. "Patients must play an active role in seeking out and obtaining the care they need and deserve. They also need to feel comfortable talking with their physicians because active conversation about treatment options is the only way that the best treatment for them can be identified."

"I always assumed that all treatment would work the same so I didn't go back to my doctor to tell her that I wasn't getting the relief I needed," said Vanessa Simmons, a 27 year old who has suffered with migraine since high school. "When she first suggested I try Relpax, I didn't expect it would help me, but thankfully I was wrong! My migraine used to last a couple of days but now my pain is usually gone in 60 minutes."*

For some people, Relpax starts to work in as little as 30 minutes and most people get relief within two hours.


Be Stronger than Your Migraine is designed to help sufferers like Vanessa overcome their frustration and seek help from a physician. The new brochure is part of a free tool kit called 'Understanding in a Box' that also includes tips for family and friends, the children's book Mama Lion's Migraine and information about Relpax(R) (eletriptan HBr), Pfizer's migraine medication. The kit can be ordered at http://www.migrainerelief.com/ or by calling 1-866-519-0300.

About Relpax - Relpax(R) (eletriptan HBr) is a product in the class of drugs known as "triptans." It has been studied in clinical trials involving more than 9,000 patients and more than 70,000 migraine attacks and shown to provide relief of migraine pain and its associated symptoms of nausea and sensitivity to light and sound. Clinical studies have also shown that more people experienced relief with one dose of Relpax than those taking Imitrex(R) (sumatriptan).

The most common side effects reported in clinical trials with Relpax compared with placebo included dizziness (6 percent vs. 3 percent), nausea (5 percent vs. 5 percent), weakness (5 percent vs. 3 percent), and tiredness (6 percent vs. 3 percent). The adverse events seen with Relpax are similar to adverse events reported with triptans as a class.

As with other triptans, it is strongly recommended that Relpax not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors, unless a clinical evaluation provides evidence that the patient is free of underlying cardiovascular disease. Relpax should not be used within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir.

Patient summary of information for Relpax(R) (eletriptan HBr) can be found by visiting http://www.stronger.relpax.com/ or calling 1-866-802-6900.

* Individual results may vary.

Relpax and TAO are registered trademarks of Pfizer Inc. Imitrex(R) is a registered trademark of GlaxoSmithKline. All other brands are trademarks of their respective owners.

Source: Pfizer Inc, CONTACT: Alison Lehanski of Pfizer, +1-212-733-8087; Janene Ferrara of Marina Maher Communications, +1-212-485-6843, for Pfizer Inc - NEW YORK, June 29 /PRNewswire-FirstCall/